Cargando…

Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Corneal Staining in Patients With Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and Phase 3 Studies

Keratoconjunctivitis sicca affects 5% to 33% of the population and is often accompanied by symptoms such as burning and dryness. This pooled analysis evaluated total and central corneal fluorescein staining (CFS) in patients receiving OTX-101 0.09% or vehicle in phase 2b/3 and 3 studies and whether...

Descripción completa

Detalles Bibliográficos
Autores principales:	Malhotra, Ranjan, Devries, Douglas K., Luchs, Jodi, Kabat, Alan, Schechter, Barry A., Shen Lee, Bridgitte, Shettle, Lee, Smyth-Medina, Robert, Ogundele, Abayomi, Darby, Charles, Bacharach, Jason, Karpecki, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cornea 2019
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749965/ https://www.ncbi.nlm.nih.gov/pubmed/31306284 http://dx.doi.org/10.1097/ICO.0000000000001989

Ejemplares similares

Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca
por: Sheppard, John, et al.
Publicado: (2021)

A phase 1, open-label, single-arm study evaluating the ocular safety of OTX-101 and systemic absorption of cyclosporine in healthy human volunteers
por: Karpecki, Paul M, et al.
Publicado: (2019)

Effect of OTX-101 in Patients with Dry Eye Disease at Day 14 of Treatment: Ocular Surface Endpoint Results from the Phase 2b/3 Clinical Trial
por: Schechter, Barry A, et al.
Publicado: (2022)

A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease
por: Tauber, Joseph, et al.
Publicado: (2018)

Managing Dry Eye Disease and Facilitating Realistic Patient Expectations: A Review and Appraisal of Current Therapies
por: Shen Lee, Bridgitte, et al.
Publicado: (2020)

A Review of Topical Cyclosporine A Formulations—A Disease-Modifying Agent for Keratoconjunctivitis Sicca
por: Jerkins, Gary W, et al.
Publicado: (2020)

A New Conception of Keratoconjunctivitis Sicca
Publicado: (1946)

Changes in tear protein profile in dogs with keratoconjunctivitis sicca following topical treatment using cyclosporine A
por: Sussadee, Metita, et al.
Publicado: (2021)

The role of inflammation and antiinflammation therapies in keratoconjunctivitis sicca
por: Gumus, Koray, et al.
Publicado: (2009)

Tear ferning in normal dogs and dogs with keratoconjunctivitis sicca
por: Williams, David, et al.
Publicado: (2017)

Effect of Oral Choline Alfoscerate on Patients with Keratoconjunctivitis Sicca
por: Choi, Jin Ju, et al.
Publicado: (2020)

Immune-mediated keratoconjunctivitis sicca in dogs: current perspectives on management
por: Dodi, Pier Luigi
Publicado: (2015)

Differentially Expressed Tear Proteins in Sjögren's Syndrome Keratoconjunctivitis Sicca
por: Yoon, Stephen P., et al.
Publicado: (2023)

Use of linseed oil to treat experimentally induced keratoconjunctivitis sicca in rabbits
por: Neves, Magda Luzia, et al.
Publicado: (2013)

Microvascular autologous submandibular gland transplantation in severe cases of keratoconjunctivitis sicca
por: Su, Jia-Zeng, et al.
Publicado: (2015)

Differentially Expressed Gene Pathways in the Conjunctiva of Sjögren Syndrome Keratoconjunctivitis Sicca
por: de Paiva, Cintia S., et al.
Publicado: (2021)

Recurrent microbial keratitis in eyes with keratoconjunctivitis sicca with coexisting ocular surface pathology
por: Nanavaty, Mayank A., et al.
Publicado: (2014)

Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis
por: Karpecki, Paul, et al.
Publicado: (2023)

Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
por: White, Darrell E, et al.
Publicado: (2019)

Ocular Distribution of Cyclosporine Following Topical Administration of OTX-101 in New Zealand White Rabbits
por: Weiss, Sidney L., et al.
Publicado: (2019)

Use of Adipose-Derived Mesenchymal Stem Cells in Keratoconjunctivitis Sicca in a Canine Model
por: Villatoro, Antonio J., et al.
Publicado: (2015)

Immunohistochemical evaluation of lymphocyte populations in the nictitans glands of normal dogs and dogs with keratoconjunctivitis sicca
por: Williams, David L., et al.
Publicado: (2018)

Apricot Kernel Extract and Amygdalin Inhibit Urban Particulate Matter-Induced Keratoconjunctivitis Sicca
por: Hyun, Soo-Wang, et al.
Publicado: (2019)

Combination of Nanomicellar Technology and In Situ Gelling Polymer as Ocular Drug Delivery System (ODDS) for Cyclosporine-A
por: Terreni, Eleonora, et al.
Publicado: (2021)

Clinical evaluation of a nutraceutical diet as an adjuvant to pharmacological treatment in dogs affected by Keratoconjunctivitis sicca
por: Destefanis, Simona, et al.
Publicado: (2016)

Autonomic reinnervation and functional regeneration in autologous transplanted submandibular glands in patients with severe keratoconjunctivitis sicca
por: Zhang, Xueming, et al.
Publicado: (2018)

Severity of Sjögren’s Syndrome Keratoconjunctivitis Sicca Increases with Increased Percentage of Conjunctival Antigen-Presenting Cells
por: Pflugfelder, Stephen C., et al.
Publicado: (2018)

Topical applications of allogeneic adipose-derived mesenchymal stem cells ameliorate the canine keratoconjunctivitis sicca
por: Wei, Li-Ning, et al.
Publicado: (2022)

Treatment of patients with keratoconjunctivitis sicca with Optive™: results of a multicenter, open-label observational study in Germany
por: Kaercher, Thomas, et al.
Publicado: (2009)

Disruption of TGF-β Signaling Improves Ocular Surface Epithelial Disease in Experimental Autoimmune Keratoconjunctivitis Sicca
por: De Paiva, Cintia S., et al.
Publicado: (2011)

Erratum to: Clinical evaluation of a nutraceutical diet as an adjuvant to pharmacological treatment in dogs affected by Keratoconjunctivitis sicca
por: Destefanis, Simona, et al.
Publicado: (2016)

Comparison between fish and linseed oils administered orally for the treatment of experimentally induced keratoconjunctivitis sicca in rabbits
por: Silva, Danielle Alves, et al.
Publicado: (2017)

Reproducibility of Ocular Surface Staining in the Assessment of Sjögren Syndrome–Related Keratoconjunctivitis Sicca: Implications on Disease Classification
por: Rasmussen, Astrid, et al.
Publicado: (2019)

Ocular Clinical Signs and Diagnostic Tests Most Compatible With Keratoconjunctivitis Sicca: A Latent Class Approach
por: Gonzales, John A., et al.
Publicado: (2020)

Assessment of meibomian gland morphology by noncontact infrared meibography in Shih Tzu dogs with or without keratoconjunctivitis sicca
por: Kitamura, Yasunari, et al.
Publicado: (2019)

Oral cyclosporine therapy for refractory severe vernal keratoconjunctivitis
por: Gokhale, Nikhil S, et al.
Publicado: (2012)

Efficacy and safety of 0.05% micellar nano-particulate (MNP) cyclosporine ophthalmic emulsion in the treatment of moderate-to-severe keratoconjunctivitis sicca: a 12-week, multicenter, randomized, active-controlled trial
por: Rao, A Tarakeswara, et al.
Publicado: (2023)

Comparison of topical 0.03% tacrolimus and homologous injectable platelet-rich plasma in the treatment of keratoconjunctivitis sicca in dogs
por: Estanho, Giovana José Garcia, et al.
Publicado: (2023)

Clinical‐dosimetric relationship between lacrimal gland dose and keratoconjunctivitis sicca in dogs with sinonasal tumors treated with radiation therapy
por: Poirier, Valerie J., et al.
Publicado: (2020)

Revisiting Keratoconjunctivitis sicca associated with Human T-Cell Lymphotropic Virus Type 1: prevalence, clinical aspects and proviral load
por: Rathsam-Pinheiro, Regina Helena, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qcq1u51a7at2b4df2s48d93epk